UNIVERSITY OF UTAH

23 carbon storage projects shortlisted for $518 million DOE support, aiming to store 50 million tons of CO2 annually. Key projects include West Virginia's $44 million hub and North Dakota's Project Tundra with $49 million.

University of Utah researchers Drs. Dustin Williams, Nicholas Ashton, and David Rothberg received DoD awards for Purgo Pouch development. Dr. Annie Isabel Fukushima featured in Hulu's 'Out There: Crimes of the Paranormal'. Dr. Rebecca Simmons awarded NIH SBIR grant for contraception research with OvaryIt.

Various projects aim to assess and establish the feasibility of commercial large-scale CO₂ storage complexes across the U.S., focusing on geological analysis, risk assessment, and community engagement to store over 50 million metric tons of CO₂.

Labs face operational changes to comply with FDA's expanded oversight of lab developed tests (LDTs), which now require medical device standards. Health industry groups warn of added costs and administrative burdens, potentially reducing patient access to innovative tests. Lab organizations are challenging the rule in court, arguing it duplicates existing CLIA regulations. The FDA maintains its rule complements CLIA, focusing on test design and development. Labs are preparing for compliance, despite uncertainties, and await further FDA guidance.

The Undiagnosed Hackathon was conceptualized and designed by H.C., M. Cederroth, A.N., and A.M.D.V. Biological samples and phenotype data were collected by various authors, processed and analyzed under the coordination of A.M.D.V. et al. All authors participated in data analysis and interpretation, with A.M.D.V. et al. drafting the manuscript. A.N., H.C., and M. Cederroth secured funding.

Livionex successfully concluded a Phase 2 meeting with the FDA for C-KAD, a 2.6% EDTA ophthalmic solution, advancing it to Phase 3. C-KAD aims to improve vision in early-to-moderate cataract patients by reducing lens clouding. The company aligned with the FDA on Phase 3 program elements, including trial design, dose duration, and safety requirements. Positive Phase 1/2 data supports the Phase 3 program, with a sub-analysis showing significant visual function improvement in C-KAD group compared to placebo.

Cabozantinib plus atezolizumab did not show significant overall survival benefit over second novel hormonal therapy in mCRPC patients, despite improved progression-free survival. Subgroup analyses indicated a survival advantage for patients with liver and bone metastases. The combination may be useful for selected mCRPC patients who have progressed on an NHT.

Pfizer's phase 3 TALAPRO-2 trial shows significant OS improvement with Talzenna (PARP inhibitor) and Xtandi (ARPI) in metastatic castration-resistant prostate cancer (mCRPC), regardless of HRR gene mutation status. The combination's safety profile remains consistent with individual drugs, and the data will support potential label expansion.

Talazoparib plus enzalutamide improved overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients compared to enzalutamide alone in the TALAPRO-2 trial. OS improvement was observed in all-comers and in HRR gene mutation carriers. Data will be presented at a medical conference and shared with health authorities to support label expansion for the combination.